Adempas Tablet, Film Coated
NDC Package 50419-252-01
Package Information
Adempas (riociguat) tablets is riociguat is used to treat high blood pressure in the lungs (pulmonary hypertension). This formulation utilizes a tablet, film coated delivery system. Marketed by Bayer Healthcare Pharmaceuticals Inc., this product is identified by NDC 50419-252 and is authorized under FDA application NDA204819.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50419 - Bayer Healthcare Pharmaceuticals Inc.
- 50419-252 - Adempas
- 50419-252-01 - 90 TABLET, FILM COATED in 1 BOTTLE
- 50419-252 - Adempas
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (50419-252). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50419-252-01 identifies a specific commercial package of 90 tablet, film coated in 1 bottle of Adempas, a human prescription drug labeled by Bayer Healthcare Pharmaceuticals Inc.. This product is billed for "EA" each discreet unit and contains an estimated amount of 90 billable units per package. This tablet, film coated is formulated for oral use and contains riociguat as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bayer Healthcare Pharmaceuticals Inc. on October 08, 2013. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Riociguat is used to treat high blood pressure in the lungs (pulmonary hypertension). It can also be used to treat a certain type of high blood pressure in the lungs caused by blood clots (chronic thromboembolic pulmonary hypertension) when surgery has not been fully successful or is impossible. Riociguat works by relaxing and widening the blood vessels in your lungs so blood can flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.
How is this Bayer Healthcare Pharmaceuticals Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50419025201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.